News
BCLI
0.790
-3.66%
-0.030
Weekly Report: what happened at BCLI last week (0803-0807)?
Weekly Report · 5h ago
Lunai Bioworks Signs Master Collaboration Agreement With BrainStorm Therapeutics; BioSymetrics Publishes Parkinson's Disease AI White Paper, Initial Data Expected In 1H 2027
Benzinga · 5d ago
Weekly Report: what happened at BCLI last week (0727-0731)?
Weekly Report · 08/03 09:32
BrainStorm Cell Reshapes Leadership to Advance NurOwn Trial
TipRanks · 07/30 21:27
Press Release: BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
Dow Jones · 07/28 12:00
*BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts As Executive Chairman >BCLI
Dow Jones · 07/28 12:00
Weekly Report: what happened at BCLI last week (0720-0724)?
Weekly Report · 07/27 09:34
Weekly Report: what happened at BCLI last week (0713-0717)?
Weekly Report · 07/20 09:32
Weekly Report: what happened at BCLI last week (0706-0710)?
Weekly Report · 07/13 09:33
Weekly Report: what happened at BCLI last week (0629-0703)?
Weekly Report · 07/06 09:35
Weekly Report: what happened at BCLI last week (0622-0626)?
Weekly Report · 06/29 09:33
Weekly Report: what happened at BCLI last week (0615-0619)?
Weekly Report · 06/22 09:37
Weekly Report: what happened at BCLI last week (0608-0612)?
Weekly Report · 06/15 09:37
Weekly Report: what happened at BCLI last week (0601-0605)?
Weekly Report · 06/08 09:35
BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine
PR Newswire · 06/02 13:00
Weekly Report: what happened at BCLI last week (0525-0529)?
Weekly Report · 06/01 09:37
BrainStorm Adds Former FDA Leader to Board
TipRanks · 05/28 21:16
Lunai Bioworks and BrainStorm launch foundation for neurological diseases
TipRanks · 05/28 14:26
BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts As Board Director
Benzinga · 05/28 11:49
Weekly Report: what happened at BCLI last week (0518-0522)?
Weekly Report · 05/25 09:39
More
Webull provides a variety of real-time BCLI stock news. You can receive the latest news about Brainstorm Cell Therapeutics I through multiple platforms. This information may help you make smarter investment decisions.
About BCLI
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease; progressive multiple sclerosis (PMS); Alzheimer’s disease (AD); and other neurodegenerative diseases. Its NurOwn, a cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived MSCs to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. It has completed a Phase III pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells. The Company's wholly owned subsidiary, Brainstorm Cell Therapeutics Ltd. holds exclusive rights to commercialize NurOwn technology.